Search hospitals > Louisiana > Shreveport
Louisiana Research Center, LLC
Claim this profileShreveport, Louisiana 71105
Global Leader in Crohn's Disease
Global Leader in Inflammatory Bowel Disease
Conducts research for Ulcerative Colitis
Conducts research for Ulcer
Conducts research for Non-alcoholic Fatty Liver Disease
95 reported clinical trials
2 medical researchers
Summary
Louisiana Research Center, LLC is a medical facility located in Shreveport, Louisiana. This center is recognized for care of Crohn's Disease, Inflammatory Bowel Disease, Ulcerative Colitis, Ulcer, Non-alcoholic Fatty Liver Disease and other specialties. Louisiana Research Center, LLC is involved with conducting 95 clinical trials across 63 conditions. There are 2 research doctors associated with this hospital, such as Humberto I. Aguilar and Arthur Poch, MD.Top PIs
Humberto I. AguilarLouisiana Research Center, LLC2 years of reported clinical research
Studies Colorectal Cancer
Studies Crohn's Disease
9 reported clinical trials
13 drugs studied
Arthur Poch, MDLouisiana Research Center, LLC16 years of reported clinical research
Studies Irritable Bowel Syndrome
Studies Syndrome
1 reported clinical trial
1 drug studied
Clinical Trials running at Louisiana Research Center, LLC
Liver Cirrhosis
Ulcerative Colitis
Nonalcoholic Steatohepatitis
Cholangitis
Primary Biliary Cirrhosis
Non-alcoholic Fatty Liver Disease
Fatty Liver Disease
Obesity
Crohn's Disease
Inflammatory Bowel Disease
Resmetirom
for NASH Cirrhosis
This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.
Recruiting1 award Phase 39 criteria
Elafibranor
for Primary Biliary Cholangitis
The participants of this study will have confirmed Primary Biliary Cholangitis (PBC). Participants will also have inadequate response or intolerance to ursodeoxycholic acid (UDCA) a drug used to treat PBC. PBC is a disease that progresses slowly. It causes damage to the bile ducts in the liver, leading to a build-up of bile acids which causes further damage. The liver damage in PBC may lead to scarring (cirrhosis). PBC may also be associated with multiple symptoms. Many people with PBC may require liver transplant or may die if the disease progresses and a liver transplant is not done. This study will compare a daily dose of elafibranor (the study drug) to a daily dose of placebo (a dummy treatment). Each participant will be in the study up to about 7 years. The main aim of this study is to determine if elafibranor is better than placebo in preventing clinical outcome events showing disease worsening (including progression of disease leading to liver transplant or death). This study will also study the safety of long-term treatment with elafibranor, as well as the impact on symptoms such as itching and tiredness.
Recruiting1 award Phase 36 criteria
Seladelpar
for Primary Biliary Cholangitis
To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)
Recruiting1 award Phase 35 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Louisiana Research Center, LLC?
Louisiana Research Center, LLC is a medical facility located in Shreveport, Louisiana. This center is recognized for care of Crohn's Disease, Inflammatory Bowel Disease, Ulcerative Colitis, Ulcer, Non-alcoholic Fatty Liver Disease and other specialties. Louisiana Research Center, LLC is involved with conducting 95 clinical trials across 63 conditions. There are 2 research doctors associated with this hospital, such as Humberto I. Aguilar and Arthur Poch, MD.